Viatris, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment, reported Reuters. The proposed settlement would resolve litigation that began following public outrage in 2016 over Mylan's decision to raise the list price for a pair of EpiPen to $600 from $100 in 2008, fueling a debate about rising US drug costs. Related: Viatris Gets A Win In Long-Running EpiPen Antitrust Suit The case, brought on behalf of consumers and third-party payers like insurers, had until recently been slated to go on trial this month, with plaintiffs seeking $1 billion in damages. The sum was seen as especially significant as the amount awarded can be multiplied under certain antitrust laws, with up to treble damages awarded for the worst damages.